SEC Form 4 · accession 0001652917-15-000008
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel P Van Plew
Officer — SVP & General Mgr Industrial O
Period of report
Nov 6, 2015
Accepted (ET)
Nov 10, 2015 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 6, 2015 | M | 5,700 | $30.63 | A | 5,700 | D | |
| Common Stock | Nov 6, 2015 | F | 311 | $559.49 | D | 5,389 | D | |
| Common Stock | Nov 6, 2015 | F | 2,778 | $559.49 | D | 2,611 | D | |
| Common Stock | Nov 6, 2015 | M | 5,486 | $30.63 | A | 8,097 | D | |
| Common Stock | Nov 6, 2015 | F | 300 | $559.49 | D | 7,797 | D | |
| Common Stock | Nov 6, 2015 | F | 2,674 | $559.49 | D | 5,123 | D | |
| Common StockF1 | Nov 10, 2015 | S | 850 | $551.45 | D | 4,273 | D | |
| Common Stock | Nov 10, 2015 | S | 50 | $552.50 | D | 4,223 | D | |
| Common StockF2 | Nov 10, 2015 | S | 2,000 | $554.39 | D | 2,223 | D | |
| Common Stock | Nov 10, 2015 | S | 1,000 | $556.00 | D | 1,223 | D | |
| Common StockF3 | Nov 10, 2015 | S | 1,223 | $557.14 | D | 0 | D | |
| Common Stock | holding | — | — | — | 18,705 | I | by GRAT | |
| Common Stock | holding | — | — | — | 1,426 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F4 | $30.63 | Nov 6, 2015 | M | 5,700 | D | — | Dec 14, 2020 | Common Stock | 5,700 | 47,681 | D |
| Non-Qualified Stock Option (right to buy)F5 | $30.63 | Nov 6, 2015 | M | 5,486 | D | — | Dec 14, 2020 | Common Stock | 5,486 | 42,195 | D |
Explanation of responses
- F1Represents volume-weighted average price of sales of 850 shares of Company stock on November 10, 2015 at prices ranging from $551.01 to $552.00. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 10, 2015 at each separate price.
- F2Represents volume-weighted average price of sales of 2,000 shares of Company stock on November 10, 2015 at prices ranging from $554.07 to $554.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 10, 2015 at each separate price.
- F3Represents volume-weighted average price of sales of 1,223 shares of Company stock on November 10, 2015 at prices ranging from $557.06 to $558.00. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 10, 2015 at each separate price.
- F4The option became exercisable with respect to all shares underlying the option on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013.
- F5The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.